<unk>  is a cancer immunotherapy product produced by Oxford BioMedica. It is a novel cancer vaccine in clinical development with potential application in most solid tumor types and delivers a novel proprietary tumor-associated antigen, 5T4, using a pox virus vector. 5T4 is broadly distributed throughout a wide range of solid cancers and the presence of the 5T4 antigen is correlated with poor prognosis.
TroVax
SureSmile
Camp Setebaid
Lovaza
Lovemap
Caduet
Alloplant
Biricodar